| 000 | 01671cam a2200337 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223031001.0 | ||
| 008 | 140512s2013 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.11.04.M.Sc.2013.Ra.S | ||
| 100 | 0 | _aRagab Abdelhafiez Shokr | |
| 245 | 1 | 0 |
_aSafety of statins in dyslipidemic patients with chronic hepatitis C viral infection / _cRagab Abdelhafiez Shokr ; Supervised Hesham Salah Eldin Taha , Sameh Wadae Bakhoum |
| 246 | 1 | 5 | _aدراسة درجة امان عقار الستاتين لدى مرضى الالتهاب الكبدى الفيروسى (سي) ذوى الكولسترول المرتفع |
| 260 |
_aCairo : _bRagab Abdelhafiez Shokr , _c2013 |
||
| 300 |
_a145 P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Cardiology | ||
| 520 | _aSome studies have shown that patients with hepatitis C are at increased risk cardiovascular disease based on increased carotid intima- media thickness⁴ . These increases in markers of early atherosclerosis in chronic hepatitis C may make 3- hydroxy -3- methylglutary 1 coenzyme A reductase inhibitors (statins) of a particular benefit in this patient population | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aDyslipidemic | |
| 653 | 4 | _aHepatitis C | |
| 653 | 4 | _aStatins | |
| 700 | 0 |
_aHesham Salah Eldin Taha , _eSupervisor |
|
| 700 | 0 |
_aSameh Wadae Bakhoum , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSoheir _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c46019 _d46019 |
||